Learned Helplessness (LH) Model Development Service
Are you currently facing long drug development cycles and challenges in identifying effective therapeutic targets for CNS disorders? Our learned helplessness (LH) model development service helps you accelerate drug discovery by providing a highly predictive and translatable platform for preclinical testing. We achieve this through advanced behavioral phenotyping, meticulous methodological design, and comprehensive neurobiological readouts.
The LH model is a well-established and widely used animal model for studying depression and the efficacy of antidepressant treatments. It is based on the theory that exposure to inescapable and unpredictable stress leads to a state of passivity and a deficit in escape behavior. This behavioral phenotype mimics core symptoms of major depressive disorder in humans, making it a powerful tool for preclinical research. The model's predictive validity has been demonstrated in its sensitivity to a range of clinically effective antidepressants.
How Our LH Model Development Service Can Assist Your Project
Our service is designed to provide you with a robust platform for testing novel therapeutic compounds. We deliver a clear and reliable assessment of your compound's efficacy in mitigating depression-like behaviors. You can expect a deep, data-driven understanding of its potential.
Discover How We Can Help - Request a Consultation.
Workflow
| Required Starting Materials | To initiate a project, clients typically provide us with the compound of interest, its administration route and dosage information, and a summary of its proposed mechanism of action. This information allows us to design a study that is precisely tailored to your research goals. |
| Final Deliverables | Upon completion, you will receive a comprehensive final report detailing the experimental design, a complete set of raw and analyzed behavioral data, and an expert analysis of the neurobiological readouts. |
| Estimated Timeframe | The typical timeframe for a project ranges from 8 to 12 weeks, depending on the complexity of the experimental design, the number of compounds to be tested, and the specific readouts requested. |
Why Choose Us?
At Creative Biolabs, our expertise in animal model development sets us apart. We don't just run tests; we develop a scientifically rigorous platform that provides you with the highest quality, most reliable data.
Experience the Advantage - Get a Quote Today.
Customer Reviews
- Using CBL's LH Model Development Service in our research has significantly improved the predictive validity of our compound screening, helping us to prioritize the most promising candidates for our depression program. (2024), A***w K.
- The team's meticulous attention to detail in their LH protocol, especially in separating fear conditioning from true helplessness, has provided us with exceptionally reliable and translatable data. (2024), D***d L.
- Their expert guidance from study design to final data analysis facilitated our project, saving us valuable time and resources. The comprehensive report was invaluable. (2024), J***e B.
Learned Helplessness (LH) Model
The core of our service is the Learned Helplessness (LH) model itself. It is a robust and long-standing paradigm that involves exposing an animal to repeated, unavoidable aversive stimuli. Over time, a subset of the animals develops a "helpless" phenotype, characterized by a failure to escape from a mild aversive stimulus, even when an escape route is available. This passive coping strategy is considered an endophenotype of depression. We are experts in not just implementing this model but in optimizing it for your specific research needs. We use a shuttle box apparatus with a shock floor that is precisely calibrated to deliver the aversive stimulus.
Fig.1 Characterization of behavioral responses in the learned helplessness procedure.1
What We Can Offer
We provide a comprehensive and customized approach to LH model development, ensuring your research is built on a foundation of scientific excellence and reliability.
- One-stop Service: We offer an integrated, end-to-end service, handling everything from initial protocol design to final data delivery.
- Customized Protocol Development: We work closely with you to optimize the model for your specific compound, including optimizing the stressor regimen and behavioral readouts.
- Reliable and Stable Phenotyping: We guarantee the stability and reliability of the learned helplessness phenotype through our well-established protocols and meticulous attention to detail.
- High-Standard Quality Control: We utilize advanced quality control tools to ensure the highest standards of data integrity and reliability throughout the entire process.
- Flexible Service Modes: Our service can be run in various modes, including a basic screening approach or a comprehensive deep dive with advanced readouts, to maximize the yield of your project.
Related Services
To complement your research, we recommend our other specialized services.
- Target Identification & Validation
- Compound Screening & Profiling
- Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
- Neuroinflammation Research Models
FAQs
Q What species do you use for your Learned Helplessness models?
Q What types of readouts are available beyond simple behavioral metrics?
We are ready to provide detailed information, answer your questions, and discuss your specific project needs.
Contact Our Team for More Information and to Discuss Your Project.
Reference
- Kim, Yongsoo, et al. "Whole-brain mapping of neuronal activity in the learned helplessness model of depression." Frontiers in neural circuits 10 (2016): 3. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fncir.2016.00003
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
